Lecture Title: RNA Medicine: RNA Editing, RNA Vaccine and RNA Therapeutics
Date & Time: November 14, 2023 (Tuesday), 13:30-15:00
Location: Multifunctional Hall, Wang Changlai Building
Medical Department Speaker: Qu Liang
Personal Profile: Qu Liang is a researcher and doctoral supervisor at the Basic Medical College of Fudan University. From 2011 to 2015, he studied at the Medical Department of Soochow University, where he received his Bachelor's degree in Biotechnology (Immune Engineering). He then pursued his Ph.D. in Biochemistry and Molecular Biology at the College of Life Sciences of Peking University from 2015 to 2020. Between 2020 and 2022, he conducted postdoctoral research at Peking University's College of Life Sciences & the Biomedical Pioneering Innovation Center (BIOPIC). In November 2022, he joined the Basic Medical College of Fudan University, establishing his research group and undertaking independent research. Dr. Qu Liang has been dedicated to the development of cutting-edge biotechnologies for RNA editing and circular RNA (circRNA) vaccines. Over the past five years, he has achieved three research outcomes in the field of RNA therapeutics: (1) Developed an RNA single-base editing technology—LEAPER—that does not rely on the CRISPR/Cas system, addressing off-target issues associated with the introduction of exogenous editing enzymes (such as Cas nucleases, APOBEC/ADAR deaminases, etc.). This study was published in Nature Biotechnology, with the applicant as the first author (Quet al., 2019), and was selected for the "National Thirteenth Five-Year Plan for Scientific and Technological Innovation Achievements Exhibition"; (2) Developed an upgraded version of LEAPER technology—LEAPER 2.0, using this technology to achieve efficient, durable, and precise targeted editing in human primary cells, organoids, and Hurler syndrome mice. This study was published in Nature Biotechnology, with the applicant as the co-first author (Yi and Quet al., 2022); (3) Developed a circRNA vaccine technology platform, expanding new areas in RNA therapeutic technology. This study was published in the journal Cell, with the applicant as the first author (Quet al., 2022).
